

29 October 2020

## Grants awarded to support clinical progression of lead drug

PYC Therapeutics Limited (ASX:PYC) (**PYC** or the **Company**) and its subsidiary Vision Pharma Pty Ltd (PYC's 90% owned joint venture with the Lions Eye Institute) have been awarded two competitive grants in support of the progression of the Company's lead drug development program into clinical trials. This drug development program is a disease-modifying therapy for Retinitis Pigmentosa type 11 (RP11) known as VP-001.

The two grants include:

- \$86,200 awarded by Microscopy Australia in support of obtaining high resolution microscopic images of cells from patients with RP11 to illustrate the impact of VP-001 on the target cells; and
- ~\$40,000 from Retina Australia to assist in conducting the genetic sequencing required to confirm patient eligibility for the planned upcoming phase 1 clinical trial.

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited*

**ENDS** For further information, please contact:

### INVESTORS

Kaggen Ausma  
CBO  
info@pyctx.com

### About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome 'the delivery challenge' and provide access for a wide range of potent and precise drug 'cargoes' to the 'undruggable genome' – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.

### **Forward looking statements**

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 6151 0994

[pyctx.com](http://pyctx.com)

**PYC Therapeutics Limited**

ACN 098 391 961